{"product_id":"phr-bcg-matrix","title":"(PHR) Phreesia, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Phreesia, Inc. BCG Matrix helps you see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital-allocation decisions. What you see on this page is a real preview of the analysis, not just sample marketing copy, so you can review the format before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore Phreesia Platform across US and Canada\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhreesia, Inc.’s Core Platform is the Star: it is the main franchise and the clearest high-share growth engine. It unifies patient intake, payments, and workflow automation in one cloud system, and it serves a U.S. and Canada healthcare market tied to $4.9 trillion in U.S. health spending. In FY2025, that scale kept the core platform the top place to put capital as digitization keeps expanding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated patient payment processing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatient financial responsibility is still climbing, and KFF said the average single deductible in employer plans was $1,787 in 2024. That keeps point-of-sale and pre-service payment tools in demand, because providers want to collect before claims age out. In Phreesia, Inc., the payment layer sits inside intake, so it drives higher use, stickiness, and retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance verification and cost estimation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhreesia, Inc.'s insurance verification and cost estimation tools cut front-end work at check-in, so staff spend less time on manual edits and more on collections. In FY2025, that matters because revenue cycle teams still face high denial and patient-pay pressure across outpatient care. This makes the workflow a clear growth leader inside the platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOnline scheduling, reminders, and referral tracking\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhreesia, Inc.'s online scheduling, reminders, and referral tracking sit in a still-growing access management niche, where digital intake can lift conversion and cut no-shows. In many outpatient settings, missed visits run near 20%, so even small gains matter. These tools also keep Phreesia embedded past the first visit, which strengthens the client tie.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBoosts booked-visit conversion\u003c\/li\u003e\n\u003cli\u003eLowers no-show rates\u003c\/li\u003e\n\u003cli\u003eExpands post-intake stickiness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical intake and PRO data in 25 specialties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhreesia’s clinical intake and PRO tools in 25 specialties are a clear Stars asset: specialty-specific workflows are harder to copy than generic intake, and they deepen daily use across care settings. The 25-specialty footprint gives Phreesia broad clinical reach, so this is a high-value expansion lane with strong cross-sell potential. One platform, many specialty paths.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e25 specialties expand clinical reach\u003c\/li\u003e\n\u003cli\u003eSpecialty workflows boost differentiation\u003c\/li\u003e\n\u003cli\u003eHigh-value area for expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhreesia’s Stars: Fast-Growing Revenue Engines in Healthcare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhreesia, Inc.’s Stars are the highest-share, fastest-growing parts of the platform: intake, payments, scheduling, and specialty workflows. In FY2025, the company served a large U.S. and Canada healthcare market tied to $4.9 trillion in U.S. health spending, while the average single employer-plan deductible reached $1,787 in 2024, keeping payment tools in demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar driver\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore platform\u003c\/td\u003e\n\u003ctd\u003eMain growth engine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayments\u003c\/td\u003e\n\u003ctd\u003eCollects faster\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e25 specialties\u003c\/td\u003e\n\u003ctd\u003eDeeper cross-sell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003ePhreesia, Inc. BCG Matrix: concise view of Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClean BCG matrix for Phreesia, Inc. that quickly spots pain points and growth bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eShows the source trail behind Phreesia’s key claims, boosting credibility and making faster, better decisions easier.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecurring SaaS renewals with established clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhreesia’s installed base keeps recurring SaaS renewals flowing, and FY2025 revenue was about $419 million, showing the scale of that cash engine. Renewal-led cash flow is what you expect from a mature software layer: slower growth, but high retention and steady billing. That makes this a classic Cash Cow, with sticky revenue and low churn risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard self-registration workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard self-registration workflows are a cash cow for Phreesia, Inc. because digital intake has become table stakes for many practices, so demand is steady even as growth slows. Phreesia reported FY2025 revenue above $400 million and a large recurring customer base, which shows this mature module still throws off dependable cash. Incremental upside is lower than newer products, but the installed base keeps it resilient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient surveys, announcements, text, and email messaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatient surveys, announcements, text, and email messaging are low-cost add-ons that Phreesia sells into its installed base, so they fit Cash Cow logic. They are sticky because they sit in daily patient workflows, and that helps support recurring margin even when growth is modest.\u003c\/p\u003e\n\u003cp\u003ePhreesia reported FY2025 revenue of about $416 million, up from about $313 million in FY2024, showing the base these tools can monetize. The unit economics work because each added message or survey module lifts revenue without a big jump in cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealth-system and multi-specialty enterprise renewals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealth-system and multi-specialty enterprise renewals are a cash cow for Phreesia, Inc. because these clients usually sign multi-year deals and renew at high rates, which supports steady, high-value revenue. This is the firm’s most mature demand pool, so growth is slower than newer categories but the cash flow is more predictable.\u003c\/p\u003e\n\u003cp\u003eThe model works because large providers tend to stay once workflows are embedded, reducing churn and lowering sales effort per renewal. In Phreesia, Inc.'s 2025 fiscal reporting, this kind of recurring enterprise base is what keeps cash generation durable even when newer segments are still scaling.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-year contracts support recurring revenue.\u003c\/li\u003e\n\u003cli\u003eLarge clients usually renew, lowering churn.\u003c\/li\u003e\n\u003cli\u003eMature market means steadier cash flow.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInstalled PhreesiaPads and Arrivals Kiosks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInstalled PhreesiaPads and Arrivals Kiosks act like a Cash Cow in Phreesia, Inc.'s BCG Matrix because the hardware is already in place across many care sites, so growth now comes more from recurring software use than from new installs. This creates a steady, mature revenue base with low incremental rollout needs.\u003c\/p\u003e\n\u003cp\u003eIn FY2025, Phreesia, Inc. reported revenue of $419.4 million, up 18% year over year, with subscription and related revenues driving most of the model. That mix fits a cash-generating asset: once a site is onboarded, usage can keep producing value without major new hardware spending.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstalled base already deployed\u003c\/li\u003e\n\u003cli\u003eRecurring usage beats new-site growth\u003c\/li\u003e\n\u003cli\u003eMature asset, steady cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhreesia’s Cash Cows Drive Steady 18% Revenue Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhreesia, Inc.'s Cash Cows are its installed base and renewal-driven software, which turned FY2025 revenue into about $419.4 million, up 18% year over year. These mature modules—self-registration, messaging, surveys, and enterprise renewals—are sticky, low-churn, and steady cash generators. Once a site is onboarded, each added workflow keeps producing revenue with limited new spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring revenue base\u003c\/td\u003e\n\u003ctd\u003e$419.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY growth\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003ePhreesia, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis Phreesia, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. No demo pages, no hidden edits—just the full, ready-to-use report. Once purchased, you’ll get the same professionally formatted file instantly. It’s designed for clear strategic analysis and immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCOVID-19 support modules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhreesia, Inc.'s COVID-19 support modules were built for the 2020 surge, but by end-2025 the demand curve is flat and the use case is far less strategic. In BCG terms, these are classic \"dogs\": low growth, low share, and likely limited cash creation. They fit a legacy bucket, not a core 2025 growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaccine delivery management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVaccine delivery management was a pandemic-era Dog for Phreesia, Inc.: demand rose with COVID-19 workflows, then normalized as vaccination volumes fell after the peak. The module now has limited long-term growth versus core intake and payments, which sit closer to the company’s durable growth engine. That makes it a weaker BCG fit than Phreesia’s core platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaccine-hesitancy identification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVaccine-hesitancy identification was a rollout-era use case, not a durable growth engine for Phreesia, Inc. It mattered when COVID-19 vaccination was a mass campaign, but demand has since shifted to routine, narrower outreach. The market is small, seasonal, and not worth heavy investment versus core patient intake and payments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eContactless check-in workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContactless check-in surged during COVID-19 in 2020, but by 2025 it is a table-stakes workflow in outpatient care, not a fresh growth driver for Phreesia, Inc. That makes it a Dogs-type feature in the BCG Matrix: low share momentum and limited new upside. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCOVID-19 drove fast adoption\u003c\/li\u003e\n\u003cli\u003eNow treated as routine\u003c\/li\u003e\n\u003cli\u003eGrowth upside looks limited\u003c\/li\u003e\n\u003cli\u003eShare momentum is weak\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTelehealth visit intake and screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTelehealth visit intake and screening at Phreesia, Inc. fits Dogs: demand jumped in 2020-2021, then normalized, and by 2025 it was still useful but clearly lagged the core platform in growth and scale. U.S. telehealth use has settled well below peak pandemic levels, so this line looks like a weak strategic bucket rather than a long-term growth driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 demand stayed below pandemic highs\u003c\/li\u003e\n\u003cli\u003eUseful, but not a core growth engine\u003c\/li\u003e\n\u003cli\u003eBest seen as a low-priority add-on\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhreesia’s COVID-Era Features Fade as 2025 Growth Drivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhreesia, Inc.’s Dogs are legacy COVID-19 features with weak 2025 pull: vaccine delivery, vaccine-hesitancy tools, contactless check-in, and telehealth intake. These were useful in 2020-2021, but demand has normalized, and none now look like a core growth engine. Their share momentum and reinvestment appeal are low.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFeature\u003c\/th\u003e\n\u003cth\u003e2025 view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID-19 modules\u003c\/td\u003e\n\u003ctd\u003eLegacy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccine tools\u003c\/td\u003e\n\u003ctd\u003eLow growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContactless check-in\u003c\/td\u003e\n\u003ctd\u003eTable-stakes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelehealth intake\u003c\/td\u003e\n\u003ctd\u003eBelow peak\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLife sciences targeted patient marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhreesia’s life sciences targeted patient marketing sells clinically relevant content to pharma, device, and biotech buyers, and FY2025 revenue was about $419 million. The budget pool is growing, but it is still smaller and more crowded than core provider software. That makes it a BCG Question Mark: attractive upside, but share is still being built. If adoption keeps rising, this line can scale into a stronger growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline appointment scheduling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOnline appointment scheduling sits in a high-growth healthcare access market, with U.S. digital health spend still rising and no-shows costing providers about $150 billion a year. But it faces crowded competition from digital access tools and EHR-linked schedulers. That makes it a clear invest-or-exit question mark for Phreesia, Inc. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReferral tracking\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReferral tracking fits Phreesia, Inc. in the Question Marks bucket: it matters in fragmented care networks, and Phreesia’s fiscal 2025 revenue was about $419 million, but referral share is not yet strong enough to call it a Star. \u003c\/p\u003e\n\u003cp\u003eAs health systems push to cut leakage and speed patient flow, referral tools can win share, but the category is still competitive and adoption is uneven. \u003c\/p\u003e\n\u003cp\u003eSo this is a growth bet, not a dominant franchise yet. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePRO expansion beyond 25 specialties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePRO in Phreesia’s suite is a question mark: it has clear clinical and research value, but it is still an emerging bet rather than a proven cash driver.\u003c\/p\u003e\n\u003cp\u003eWith use across 25 specialties today, expansion into more fields could lift demand and deepen workflow use, especially where outcomes data supports care quality and trials.\u003c\/p\u003e\n\u003cp\u003eStill, the revenue case is not yet established, so the upside depends on adoption speed, specialty fit, and monetization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e25 specialties already in play\u003c\/li\u003e\n\u003cli\u003eStrong clinical and research value\u003c\/li\u003e\n\u003cli\u003eExpansion could unlock new demand\u003c\/li\u003e\n\u003cli\u003eStill an unproven cash generator\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCanada deployments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCanada is a question mark for Phreesia, Inc. because it can grow, but the market is much smaller than the United States. Canada has about 41 million people versus about 335 million in the U.S., so the same product has a lower ceiling unless adoption rises fast. That makes Canada a potential expansion bet, not a cash engine yet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmaller base than the U.S.\u003c\/li\u003e\n\u003cli\u003eGrowth room still exists.\u003c\/li\u003e\n\u003cli\u003eNeeds stronger deployment scale.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhreesia’s Growth Bets Are Promising, But Still Unproven\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhreesia, Inc.’s Question Marks are growing but still unproven. FY2025 revenue was about $419 million, yet lines like life sciences marketing, scheduling, referral tracking, PRO, and Canada still face crowded markets or smaller addressable bases, so share must rise fast to justify the spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eQuestion Mark\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLife sciences marketing\u003c\/td\u003e\n\u003ctd\u003eFY2025 revenue about $419 million; growth pool crowded\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScheduling\u003c\/td\u003e\n\u003ctd\u003eHigh-growth access market, but strong competition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReferral tracking\u003c\/td\u003e\n\u003ctd\u003eUseful, but not yet a share leader\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRO\u003c\/td\u003e\n\u003ctd\u003eUsed in 25 specialties; monetization still early\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCanada\u003c\/td\u003e\n\u003ctd\u003eSmaller market than the U.S.; scale still limited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234820301065,"sku":"phr-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/phr-bcg-matrix.webp?v=1785728599","url":"https:\/\/dcfanalyst.com\/products\/phr-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}